FDA Approved New Breast Cancer Combination Therapy
The regulatory agency authorized Inluriyo combined with Verzenio for adults with specific metastatic breast cancer.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Do you trust that new FDA-approved drug combinations are delivering real improvements for patients?
The FDA has approved the use of Inluriyo in combination with Verzenio for adults diagnosed with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This treatment is specifically indicated for patients whose disease progressed following at least one line of endocrine therapy.
Why it matters
This combination therapy effectively doubles the median progression-free survival for patients compared to using Inluriyo as a monotherapy. The approval offers a new clinical option for individuals battling advanced forms of the disease that have proven resistant to standard endocrine treatments.
The Phase 3 EMBER-3 trial demonstrated a median progression-free survival of 11.1 months for the combination therapy, compared to 5.5 months for monotherapy. The trial sample size included 159 patients with ESR1-mutant metastatic breast cancer.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
Lilly
Eli Lilly and Company is a global pharmaceutical corporation that develops and manufactures innovative medicines, including the oncology treatments mentioned here.
The details
Patients in the EMBER-3 study were randomized to receive either Inluriyo alone or alongside Verzenio after failing previous endocrine therapy. The treatment regimen specifically addresses the needs of patients with the ESR1 mutation, a common driver of endocrine resistance in metastatic cases.
Timeline
September 18, 2026: The FDA officially cleared the Inluriyo and Verzenio combination therapy.
2027: Initial data is expected from the ongoing EMBER-4 trial.
The Big Picture
This approval follows the clinical evidence established by the EMBER-3 trial, extending its findings into real-world clinical application.
Patients with ER-positive, HER2-negative, ESR1-mutated cancer now have a new, FDA-approved therapeutic option that has shown significantly improved progression-free survival. Individuals should consult with their oncologists to determine if this combination regimen is appropriate for their specific disease history.
The takeaway
The approval of this drug combination represents a meaningful shift for patients dealing with treatment-resistant metastatic breast cancer. Patients should discuss the clinical trial data with their medical providers to understand how these findings might apply to their specific care plan.
What happens next
Lilly is currently evaluating Inluriyo in the adjuvant setting for early-stage breast cancer through the EMBER-4 trial, with initial data anticipated in 2027.
Further reading
For more information on current treatment protocols, visit the Cancer section.
Live Poll
Do you trust that new FDA-approved drug combinations are delivering real improvements for patients?
